Application 076349
- Type
- ANDA
- Sponsor
- CUSTOPHARM INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | FLUDARABINE PHOSPHATE | FLUDARABINE PHOSPHATE | INJECTABLE;INJECTION | 50MG/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A076349-001 | FLUDARABINE PHOSPHATE | FLUDARABINE PHOSPHATE | 50MG/VIAL | INJECTABLE / INJECTION | AP | 2003-08-28 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A076349-001 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A076349-001 | FLUDARABINE PHOSPHATE | 50MG/VIAL | INJECTABLE / INJECTION | AP | 2003-08-28 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A076349-001 | AP | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Fludarabine | FLUDARABINE PHOSPHATE | Fresenius Kabi USA, LLC | cf5255cc-91fd-4132-973b-764dba142eae | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | FLUDARABINE PHOSPHATE |
| Fludarabine Phosphate | FLUDARABINE PHOSPHATE | Areva Pharmaceuticals | 8039c2e3-ffe5-3997-e053-2991aa0ad9d0 | 2023-02-14 | Boxed warning, Warnings, Adverse reactions | Fludarabine Phosphate FLUDARABINE PHOSPHATE |
| Fludarabine Phosphate | FLUDARABINE PHOSPHATE | Lannett Company, Inc. | 0170c0f4-d502-4f8f-bdbf-6439f3ed33fb | 2023-01-31 | Boxed warning, Warnings, Adverse reactions | Fludarabine Phosphate FLUDARABINE PHOSPHATE |
| Fludarabine phosphate | FLUDARABINE PHOSPHATE | Actavis Pharma, Inc. | 3adca34b-4f65-4e21-8058-3c01fc7fc9bb | 2022-09-30 | Boxed warning, Warnings, Adverse reactions | Fludarabine phosphate FLUDARABINE PHOSPHATE |
| Fludarabine Phosphate | FLUDARABINE PHOSPHATE | Sagent Pharmaceuticals | 20e5acf0-90b7-45c8-be78-91eaf77c9ac0 | 2021-07-22 | Boxed warning, Warnings, Adverse reactions | Fludarabine Phosphate FLUDARABINE PHOSPHATE |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 24201-237 | fludarabine phosphate | fludarabine phosphate | Leucadia Pharmaceuticals | ANDA | Current |
| 24201-237 | fludarabine phosphate | fludarabine phosphate | Hikma Pharmaceuticals USA Inc. (dba Leucadia Pharmaceuticals) | ANDA | Current |
| 25021-237 | fludarabine phosphate | fludarabine phosphate | Sagent Pharmaceuticals | ANDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 22555 | ORIG | 2007-04-02 |